Tarsus Pharmaceuticals TARS
Valuation
Multiples measured against the stock's own five-year history
Near the top of its 5-year range · 90th percentile, 5-year average -18.4x
Near the top of its 5-year range · 100th percentile, 5-year average 5.4x
#5228 of 5330 stocks by PB (1 = cheapest)
Near the bottom of its 5-year range · 10th percentile, 5-year average 19.4x
#4079 of 5155 stocks by PS (1 = cheapest)
P/E over five years
Dashed line is the 5-year average; the shaded band is one standard deviation either side.
Morningstar fair value estimate
| Multiple | Current | Forward | 5y average | Percentile vs. own history | Industry rank |
|---|---|---|---|---|---|
| PB | 38.05 | – | 5.35 | 100% (pricier than usual) | #5228 of 5330 (1 = cheapest) |
| PE | -5.06 | -48.79 | -18.42 | 90% (pricier than usual) | – |
| PS | 5.80 | 4.47 | 19.44 | 10% (cheaper than usual) | #4079 of 5155 (1 = cheapest) |
Percentile is against this stock’s own 5-year valuation range: higher means it’s trading rich relative to its own history, lower means cheap relative to its own history — it is not a comparison against other companies. Forward multiples use consensus estimates for the next twelve months; a forward multiple below the current one usually signals analysts expect earnings to grow.
No comments yet — be the first to weigh in on TARS.
Sign in to join the discussion.